CG Oncology (NASDAQ:CGON) Director James Mulay Sells 1,964 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director James Mulay sold 1,964 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $63.50, for a total transaction of $124,714.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

James Mulay also recently made the following trade(s):

• On Friday, January 9th, James Mulay sold 11,145 shares of CG Oncology stock. The stock was sold at an average price of $52.47, for a total transaction of $584,778.15.

CG Oncology Stock Performance

NASDAQ:CGON traded up $2.74 during mid-day trading on Tuesday, hitting $68.64. The stock had a trading volume of 1,616,383 shares, compared to its average volume of 1,284,361. CG Oncology, Inc. has a twelve month low of $14.80 and a twelve month high of $69.35. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of -33.16 and a beta of 1.17. The company’s 50 day simple moving average is $55.18 and its 200 day simple moving average is $45.11.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.10. The business had revenue of $2.32 million for the quarter. As a group, equities analysts forecast that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Hedge Funds Weigh In On CG Oncology

Hedge funds have recently made changes to their positions in the stock. PNC Financial Services Group Inc. increased its position in CG Oncology by 15.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after purchasing an additional 433 shares during the period. Comerica Bank increased its position in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after buying an additional 515 shares during the period. LPL Financial LLC raised its stake in CG Oncology by 9.8% during the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock worth $257,000 after buying an additional 551 shares during the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new position in CG Oncology in the fourth quarter valued at $27,000. Finally, CWM LLC boosted its position in CG Oncology by 10.9% during the third quarter. CWM LLC now owns 6,865 shares of the company’s stock valued at $277,000 after acquiring an additional 672 shares during the last quarter. 26.56% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

CGON has been the topic of several recent research reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $82.00 target price on shares of CG Oncology in a report on Monday, January 12th. Piper Sandler lifted their price objective on CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a report on Friday, January 16th. Royal Bank Of Canada upped their target price on CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Wedbush assumed coverage on shares of CG Oncology in a report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price objective for the company. Finally, Morgan Stanley set a $93.00 target price on shares of CG Oncology in a research report on Friday, January 9th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, CG Oncology presently has an average rating of “Moderate Buy” and an average price target of $69.00.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.